Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MicroBLITZ: Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas

NCT03920631 is registered in ClinicalTrials.gov with Ahmed Galal, MD as lead sponsor.

NCT NCT03920631
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03920631 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MicroBLITZ: Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas
Lead sponsor
Ahmed Galal, MD
Phase
Phase 1
Overall status
Withdrawn
Start date
July 10, 2020
Completion date
May 15, 2023
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b cell lymphomas